Item 5.02. Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


 On February 10, 2021, the Board of Directors (the "Board") of Jounce
Therapeutics, Inc. (the "Company"), appointed Luisa Salter-Cid, Ph.D. as a
director and as a member of the Science and Technology committee of the Board,
effective immediately. Dr. Salter-Cid has been designated as a Class I director
to serve in accordance with the Company's Amended and Restated By-Laws until the
Company's 2021 Annual Meeting of Stockholders or until her successor has been
duly elected and qualified, or until her earlier death, removal or resignation.
Dr. Salter-Cid has served as the Chief Scientific Officer of Gossamer Bio, Inc.
("Gossamer"), a publicly-traded clinical-stage biopharmaceutical company, since
August 2018. Prior to joining Gossamer, Dr. Salter-Cid worked at Bristol-Myers
Squibb in increasing positions of responsibility from 2005 to August 2018, most
recently as Vice President and Head of Immunology, small molecule
Immuno-Oncology and Genomics Discovery where she focused on target validation
and development of innovative biologic and small-molecule therapeutics to
address significant unmet needs in autoimmune diseases and cancer. She was a
member of the Scientific Advisory Board of Enterome SA until July 2018. Dr.
Salter-Cid holds a B.S. in Biology from University of Lisbon, an M.S. in Biology
from Florida International University and a Ph.D. in Immunology from the
University of Miami School of Medicine.
In accordance with the Company's non-employee director compensation policy, Dr.
Salter-Cid will receive annual cash compensation of $35,000 as a member of the
Board and $6,000 as a member of the Science and Technology committee of the
Board, as well as reimbursement for reasonable travel and other expenses
incurred in connection with attending meetings of the Board and committees
thereof. She was granted an option to purchase 31,400 shares of the Company's
common stock, par value $0.001 per share, with an exercise price equal to the
closing price of the Company's common stock on the Nasdaq Global Select Market
on the date of her appointment, which option will vest in equal quarterly
installments during the twelve quarters following the grant date, subject to Dr.
Salter-Cid's continued service on the Board. Dr. Salter-Cid also will enter into
a standard form of indemnification agreement with the Company, in the form that
is filed as Exhibit 10.12 to the Company's Registration Statement on Form S-1
(File No. 333-215372), filed with the Securities and Exchange Commission on
December 30, 2016.
There are no arrangements or understandings between Dr. Salter-Cid and any other
person pursuant to which Dr. Salter-Cid was elected as a director. There are no
transactions in which Dr. Salter-Cid has an interest requiring disclosure under
Item 404(a) of Regulation S-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses